" class="no-js "lang="en-US"> Eli Lilly and Company Archives - Medtech Alert
Tuesday, May 28, 2024

Sort by:


Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

Telix Pharmaceuticals today announces the successful preclinical development of radiolabelled olaratumab, an antibody licensed from […]

Roche Announces Collaboration with Lilly to Enhance Early Diagnosis of Alzheimer's Disease

Roche announced today that it has entered into a collaboration with Eli Lilly and Company […]

FDA Accepts Supplemental New Drug Application for Jardiance® for Children 10 years and Older with Type 2 Diabetes

The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for […]

Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today […]

US FDA Accepts Supplemental New Drug Application for Jardiance® for Adults with Chronic Kidney Disease

The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) […]

DTx Leader Sidekick Enters Strategic Collaboration With Lilly to Support Patients With Breast Cancer

International digital therapeutics (DTx) innovator, Sidekick Health (www.sidekickhealth.com), today announces an integrated digital therapeutics solution in conjunction […]

CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency’s […]

Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined […]

US FDA Approves Jardiance ® (empagliflozin) to Treat Adults with Heart Failure Regardless of Left Ventricular Ejection Fraction

The U.S. Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) 10 mg to […]

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more